Titre |
Tranexamic Acid During Cystectomy Trial (TACT) |
Protocole ID |
TACT |
ClinicalTrials.gov ID |
NCT01869413 |
Type(s) de cancer |
Vessie/urothélial |
Phase |
Phase III |
Type étude |
Traitement |
Médicament |
Tranexamic acid |
Institution |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
1001 boul. Décarie , Montréal, QC, H4A 3J1
|
Ville |
Montréal |
Investigateur(trice) principal(e) |
Dr Wassim Kassouf
|
Coordonnateur(trice) |
Raphael Freitas
514-934-1934 poste 36686
|
Statut |
Fermé |
Critètes d'éligibilité |
- Participant ≥ 18 years at time of consent
- Participant has bladder cancer and will undergo radical cystectomy to remove bladder
- Participant is willing to receive blood products (i.e. packed red blood cells, platelets, plasma)
- Have obtained Informed Consent
|
Critètes d'exclusion |
- Participant declines consent
- Participants incapable (incompetent) of providing Informed Consent
- Participant is under 18 years
- Participant is unwilling to receive blood products due to personal reasons
- Participant has ever had a pulmonary embolism, deep venous thrombosis, thrombotic stroke, atrial fibrillation, coronary stents or has active angina
- Participant with known personal history of subarachnoid haemorrhage.
- Participant has acquired disturbances to his / her colour vision (does not apply to congenital colour blindness)
- Participant is pregnant (confirmed by βHCG test)
- Participant has a known allergy to tranexamic acid
|